DE69821793D1 - Neuronale verwendungen des bmp-11 - Google Patents

Neuronale verwendungen des bmp-11

Info

Publication number
DE69821793D1
DE69821793D1 DE69821793T DE69821793T DE69821793D1 DE 69821793 D1 DE69821793 D1 DE 69821793D1 DE 69821793 T DE69821793 T DE 69821793T DE 69821793 T DE69821793 T DE 69821793T DE 69821793 D1 DE69821793 D1 DE 69821793D1
Authority
DE
Germany
Prior art keywords
proteins
bmp
neuronal
useful
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69821793T
Other languages
English (en)
Other versions
DE69821793T2 (de
Inventor
J Celeste
M Wozney
R Thies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE69821793D1 publication Critical patent/DE69821793D1/de
Application granted granted Critical
Publication of DE69821793T2 publication Critical patent/DE69821793T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
DE69821793T 1997-11-07 1998-11-06 Neuronale verwendungen des bmp-11 Expired - Lifetime DE69821793T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96629797A 1997-11-07 1997-11-07
US966297 1997-11-07
PCT/US1998/023827 WO1999024058A2 (en) 1997-11-07 1998-11-06 Neuronal uses of bmp-11

Publications (2)

Publication Number Publication Date
DE69821793D1 true DE69821793D1 (de) 2004-03-25
DE69821793T2 DE69821793T2 (de) 2004-12-30

Family

ID=25511184

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69821793T Expired - Lifetime DE69821793T2 (de) 1997-11-07 1998-11-06 Neuronale verwendungen des bmp-11

Country Status (10)

Country Link
EP (1) EP1028744B1 (de)
JP (1) JP2001522810A (de)
AT (1) ATE259652T1 (de)
AU (2) AU1276399A (de)
CA (1) CA2309538A1 (de)
DE (1) DE69821793T2 (de)
DK (1) DK1028744T3 (de)
ES (1) ES2213927T3 (de)
PT (1) PT1028744E (de)
WO (2) WO1999024057A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040259779A1 (en) * 2001-07-06 2004-12-23 Teit Johansen Novel neurotrophic factors
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
CA2518102C (en) 2003-03-04 2009-05-12 Tanabe Seiyaku Co., Ltd. Powdery preparation for nasal administration
CA2526669A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
JP5058261B2 (ja) 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
WO2014168973A2 (en) 2013-04-08 2014-10-16 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
EP3881859B1 (de) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Zusammensetzungen zur erhöhung der neurogenese und angiogenese
US20160287667A1 (en) * 2013-11-08 2016-10-06 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
WO2019144053A1 (en) * 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274157T3 (es) * 1993-05-12 2007-05-16 Genetics Institute, Llc Composiciones de bmp-11.
SE9302550D0 (sv) * 1993-07-30 1993-07-30 Ernst Hoerlin Powder inhaler
PT716610E (pt) * 1993-08-26 2006-08-31 Genetics Inst Llc Proteinas morfogeneticas dos ossos de seres humanos para utilizacao em regeneracao neural
ES2251721T3 (es) * 1994-07-08 2006-05-01 The Johns Hopkins University School Of Medicine Factor-11 de diferenciacion del crecimiento.

Also Published As

Publication number Publication date
WO1999024058A3 (en) 1999-08-19
AU1276399A (en) 1999-05-31
JP2001522810A (ja) 2001-11-20
EP1028744A2 (de) 2000-08-23
WO1999024058A2 (en) 1999-05-20
PT1028744E (pt) 2004-06-30
ATE259652T1 (de) 2004-03-15
AU761940B2 (en) 2003-06-12
ES2213927T3 (es) 2004-09-01
CA2309538A1 (en) 1999-05-20
DK1028744T3 (da) 2004-06-21
AU1390099A (en) 1999-05-31
EP1028744B1 (de) 2004-02-18
WO1999024057A2 (en) 1999-05-20
DE69821793T2 (de) 2004-12-30

Similar Documents

Publication Publication Date Title
ATE343635T1 (de) Bmp-11 zusammenstellungen
DE69821793D1 (de) Neuronale verwendungen des bmp-11
DE69433742D1 (de) Bmp-10 zusammensetzungen
DK0429570T3 (da) Osteoinducerende præparater
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
ATE328896T1 (de) Faktor viii vom schwein und hybriden
ATE223486T1 (de) Bmp-9 zusammensetzungen
BG100974A (en) Vaccines against papillomavirus
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
IL112873A0 (en) Rapamycin-fkbp12 binding proteins their isolation and their use
EP0787802A3 (de)
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
TR200200278T2 (tr) Kalsilitik bileşimler
GR3033698T3 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections.
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
UA33041A (uk) Спосіб остеосинтезу переломів виросту плечової кістки

Legal Events

Date Code Title Description
8364 No opposition during term of opposition